---
schema_version: "secwatch.filing_event.v1"
accession: "0001104659-26-034951"
form_type: "8-K"
ticker: "QNRX"
cik: "0001671502"
company_name: "Quoin Pharmaceuticals, Ltd."
filed_at: "2026-03-26T23:59:59+00:00"
generated_at: "2026-05-15T08:50:50.716682+00:00"
event_type: "other_material"
sentiment: "positive"
materiality_score: 0.8
calibrated_materiality_score: 0.8
confidence: "high"
source: SEC EDGAR
---

# Quoin raises up to $104.5M, advances QRX003 regulatory path, reports 2025 net loss $15.8M

## Summary
- Closed private placement for up to $104.5M ($16.5M at closing, $88M warrant potential).
- FDA grants Fast Track Designation; single Phase 3 study may suffice for NDA; plan to file in 2027.
- Orphan Drug Designations for QRX003 in Netherton Syndrome in US and Europe; Rare Pediatric Disease Designation could yield $150-200M PRV.
- Pediatric Netherton study expanded to 7 children with sustained skin healing, no adverse events; Peeling Skin study to 6 subjects.
- Cash $18.7M at Dec 31, 2025; net loss Q4 $4.3M vs $2.3M YoY; full year $15.8M vs $9.0M.

## SEC filing metadata
- accession: 0001104659-26-034951
- form_type: 8-K
- ticker: QNRX
- cik: 0001671502
- company_name: Quoin Pharmaceuticals, Ltd.
- filed_at: 2026-03-26T23:59:59+00:00
- event_type: other_material
- sentiment: positive
- materiality_score: 0.8
- calibrated_materiality_score: 0.8
- confidence: high
- sec_items: 2.02, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1671502/000110465926034951/0001104659-26-034951-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1671502/000110465926034951/tm269662d1_8k.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001104659-26-034951
- JSON: https://secwatch.observer/filing/0001104659-26-034951.json
- Plain text: https://secwatch.observer/filing/0001104659-26-034951.txt

## Key facts
- Earnings Releases
  Quoin Pharmaceuticals, Ltd. reported financial results for fourth quarter and fiscal year 2025.
  - Period: fourth quarter and fiscal year 2025
  - Result: reported results
  source text: Quoin Pharmaceuticals Ltd. (the "Company") announced its fourth quarter and fiscal year 2025 financial results. A copy of the Company's press release is attached as Exhibit 99.1 hereto and incorporated by reference herein.
  evidence_url: https://www.sec.gov/Archives/edgar/data/1671502/000110465926034951/0001104659-26-034951-index.htm

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.